Free Trial
→ A new income category is drawing serious money - here's why (From Investors Alley) (Ad)tc pixel
NASDAQ:STRO

Sutro Biopharma Q3 2026 Earnings Date & Estimates

Sutro Biopharma logo
$13.28 -0.99 (-6.94%)
Closing price 04:00 PM Eastern
Extended Trading
$13.28 0.00 (0.00%)
As of 04:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sutro Biopharma is expected to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Sutro Biopharma in Q3 2026

Sutro Biopharma is expected to post earnings of -$1.6637 per share on revenue of $13.61 million. In the same quarter a year earlier Sutro Biopharma reported -$0.67 per share on revenue of $9.69 million. Sutro Biopharma last reported on August 12, 2026, posting -$2.33 per share and missing the -$2.19 consensus estimate. Sutro Biopharma has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.6637
Expected Revenue
$13.61 million
Prior-Year EPS
-$0.67
Prior-Year Revenue
$9.69 million
Expected Revenue Growth
+40.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$2.33 (Missed by -$0.14)
Last Quarter Revenue
$9.84 million
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Sutro Biopharma Q3 2026 Earnings FAQ

Sutro Biopharma (NASDAQ:STRO) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Sutro Biopharma's Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Sutro Biopharma to post earnings of -$1.6637 per share for Q3 2026.

The consensus revenue estimate for Sutro Biopharma is $13.61 million for Q3 2026.

Sutro Biopharma Earnings Headlines

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
 |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/sutro-biopharma-announces-participation-at-the-17th-annual-world-adc-conference-1036616306
Vaxcyte Prices $1 Billion in Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
October 6, 2026  |  quiverquant.comQ
My biggest prediction yet?!
James Altucher called Facebook's rise past 100 billion dollars in 2007 and Apple's run to a trillion years later, both times facing skepticism. Now he's tracking a new Elon Musk production facility that could begin operations as soon as October 21, tied to what he calls a potential 2 quadrillion dollar opportunity by 2040, based on Dallas Fed data. Altucher has put the full story and drone footage into one presentation.tc pixel
October 12 at 1:00 AM  |  Paradigm Press (Ad)
Vaxcyte Announces Webcast and Conference Call to Present Topline Data from OPUS-1 Phase 3 Trial of VAX-31 in Adults
October 4, 2026  |  quiverquant.comQ
Sutro Biopharma, Inc. (NASDAQ:STRO) Stock Has Average Price Target of $49.50 According to Brokerages
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083876
Wells Fargo & Company Initiates Coverage on Sutro Biopharma (NASDAQ:STRO)
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31076676
See More Sutro Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sutro Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sutro Biopharma and other key companies, straight to your email.

About Sutro Biopharma

Sutro Biopharma (NASDAQ:STRO) is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company uses its proprietary cell-free protein synthesis and protein-engineering platforms to design and manufacture complex biologic medicines, including antibody-drug conjugates (ADCs) and immuno-oncology treatments.

Sutro’s principal product candidate is luveltamab tazevibulin, also known as luvelta or STRO-002, an ADC designed to target folate receptor alpha, a protein expressed in several cancers. The company has also developed additional investigational programs directed at cancer-related targets and continues to evaluate new therapies generated through its research platforms.

Founded in 2003 and headquartered in South San Francisco, California, Sutro conducts research and clinical development activities that support potential treatments for patients in the United States and other international markets. William J. Newell has served as the company’s chief executive officer and has been associated with Sutro since its early development.

View Sutro Biopharma Profile
Earnings Tools